Ultimovacs ASA (FRA:7UM) Additional Paid-In Capital : €93.34 Mil(As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Additional Paid-In Capital?

Ultimovacs ASA's quarterly additional paid-in capital declined from Sep. 2023 (€94.04 Mil) to Dec. 2023 (€93.58 Mil) but then stayed the same from Dec. 2023 (€93.58 Mil) to Mar. 2024 (€93.34 Mil).

Ultimovacs ASA's annual additional paid-in capital declined from Dec. 2021 (€105.52 Mil) to Dec. 2022 (€102.84 Mil) and declined from Dec. 2022 (€102.84 Mil) to Dec. 2023 (€93.58 Mil).

Ultimovacs ASA Additional Paid-In Capital Historical Data

The historical data trend for Ultimovacs ASA's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Additional Paid-In Capital Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

65.50

76.39

105.52

102.84

93.58

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															95.45	92.02	94.04	93.58	93.34

Ultimovacs ASA Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Ultimovacs ASA Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (FRA:7UM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (FRA:7UM) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (FRA:7UM) Headlines

No Headlines